Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

AUGUSTO E FOCIL

Allopathic & Osteopathic Physicians Family Medicine

NPI
1407906027
CMS profile
336597
Location
OXNARD, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$50.47

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $50.47 2

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
Boehringer Ingelheim Pharmaceuticals, Inc. $34.10 1
Novo Nordisk Inc $16.37 1

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

AUGUSTO E FOCIL

NPI 1407906027 · CMS profile ID 336597

Allopathic & Osteopathic Physicians / Family Medicine

OXNARD, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1407906027?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
AUGUSTO E FOCIL, NPI 1407906027, CMS profile ID 336597. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1407906027?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). AUGUSTO E FOCIL, NPI 1407906027, CMS profile ID 336597. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1407906027?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
AUGUSTO E FOCIL, NPI 1407906027, CMS profile ID 336597, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1407906027?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $50.47 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novo Nordisk Inc $16.3705/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188163199 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $34.1005/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223035116 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,005.14 67
PY2020 $147.59 10
PY2021 $845.82 44
PY2022 $3,925.76 37
PY2023 $246.04 11
PY2024 $245.24 11
PY2025 $50.47 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,708,235.50 545
PY2024 Principal investigator $1,326,172.95 90
PY2023 Principal investigator $2,591,514.80 142
PY2022 Principal investigator $1,448,426.62 96
PY2021 Recipient $668.48 1
PY2021 Principal investigator $1,836,497.66 79
PY2020 Principal investigator $3,489,260.26 87
PY2019 Principal investigator $210,837.51 13

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

545 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $20,020.56 12/31/2025 Non-covered Recipient Entity
FOMAT Medical Research
A Phase 3, Randomized, Placebo-Controlled, Double Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupiravir MK-4482 in Non-Hospitalized Adults with COVID-19 at High Risk for Disease Progression No dispute reported 06/30/2026 1232929551
Principal investigator 1 Merck Sharp & Dohme LLC $322.80 12/31/2025 Non-covered Recipient Entity
FOMAT Medical Research
A Phase 3, Randomized, Placebo-Controlled, Double Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupiravir MK-4482 in Non-Hospitalized Adults with COVID-19 at High Risk for Disease Progression No dispute reported 06/30/2026 1232929553
Principal investigator 1 PFIZER INC. $10,110.40 12/31/2025 Non-covered Recipient Entity
FOMAT Medical Research Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 1228750535
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 12/30/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220682100
Principal investigator 1 Boehringer Ingelheim International GmbH $44.70 12/30/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220682102
Principal investigator 1 Boehringer Ingelheim International GmbH $225.00 12/30/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220682104
Principal investigator 1 Boehringer Ingelheim International GmbH $310.00 12/30/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220682106
Principal investigator 1 Boehringer Ingelheim International GmbH $200.00 12/30/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220682108
Principal investigator 1 Boehringer Ingelheim International GmbH $245.00 12/30/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220682110
Principal investigator 1 Boehringer Ingelheim International GmbH $7,167.37 12/26/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220682098
Principal investigator 1 Boehringer Ingelheim International GmbH $400.00 12/26/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682418
Principal investigator 1 Boehringer Ingelheim International GmbH $2,131.52 12/19/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682416
Principal investigator 1 Boehringer Ingelheim International GmbH $400.00 12/18/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220682096
Principal investigator 1 Boehringer Ingelheim International GmbH $291.50 12/17/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220682114
Principal investigator 1 Boehringer Ingelheim International GmbH $379.62 12/17/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220682116
Principal investigator 1 Boehringer Ingelheim International GmbH $438.00 12/17/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220682118
Principal investigator 1 Boehringer Ingelheim International GmbH $48.85 12/17/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220682120
Principal investigator 1 Boehringer Ingelheim International GmbH $244.86 12/17/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682424
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 12/17/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682426
Principal investigator 1 Boehringer Ingelheim International GmbH $985.50 12/17/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682428
Principal investigator 1 Boehringer Ingelheim International GmbH $15.00 12/17/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682430
Principal investigator 1 PFIZER INC. $1,498.10 12/17/2025 Non-covered Recipient Entity
FOMAT Medical Research Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 1228726178
Principal investigator 1 Merck Sharp & Dohme LLC $100,969.00 12/15/2025 Non-covered Recipient Entity
FOMAT Medical Research
A Phase 3, Randomized, Placebo-Controlled, Double Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupiravir MK-4482 in Non-Hospitalized Adults with COVID-19 at High Risk for Disease Progression No dispute reported 06/30/2026 1232929549
Principal investigator 1 PFIZER INC. $6,084.70 12/12/2025 Non-covered Recipient Entity
FOMAT Medical Research Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 1228745105
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 12/03/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220682094
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 12/03/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682420
Principal investigator 1 PFIZER INC. $9,627.60 11/29/2025 Non-covered Recipient Entity
FOMAT Medical Research Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 1228738539
Principal investigator 1 Boehringer Ingelheim International GmbH $1,425.19 11/27/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220682028
Principal investigator 1 Boehringer Ingelheim International GmbH $677.27 11/27/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220682038
Principal investigator 1 Boehringer Ingelheim International GmbH $1,875.00 11/27/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220682046
Principal investigator 1 Boehringer Ingelheim International GmbH $1,875.00 11/27/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220682092
Principal investigator 1 Boehringer Ingelheim International GmbH $2,131.52 11/27/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682384
Principal investigator 1 Boehringer Ingelheim International GmbH $2,131.52 11/27/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682398
Principal investigator 1 Boehringer Ingelheim International GmbH $2,131.52 11/27/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682406
Principal investigator 1 Boehringer Ingelheim International GmbH $2,131.52 11/27/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682410
Principal investigator 1 Boehringer Ingelheim International GmbH $2,131.52 11/27/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682414
Principal investigator 1 Boehringer Ingelheim International GmbH $4,326.73 11/26/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220682032
Principal investigator 1 Boehringer Ingelheim International GmbH $21,250.00 11/26/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220682052
Principal investigator 1 Boehringer Ingelheim International GmbH $21,250.00 11/26/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220682074
Principal investigator 1 Boehringer Ingelheim International GmbH $198.93 11/24/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220682090
Principal investigator 1 Boehringer Ingelheim International GmbH $4,326.73 11/19/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220682030
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 11/19/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220682112
Principal investigator 1 Boehringer Ingelheim International GmbH $11,391.62 11/17/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220682058
Principal investigator 1 Boehringer Ingelheim International GmbH $90.02 11/17/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220682072
Principal investigator 1 Boehringer Ingelheim International GmbH $24,650.00 11/17/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220682076
Principal investigator 1 ModernaTX, Inc. $2,500.00 11/14/2025 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252967843
Principal investigator 1 ModernaTX, Inc. $3,000.00 11/14/2025 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252967863
Principal investigator 1 ModernaTX, Inc. $1,500.00 11/14/2025 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252967869
Principal investigator 1 Boehringer Ingelheim International GmbH $4,326.73 11/13/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220682034
Principal investigator 1 Boehringer Ingelheim International GmbH $831.00 11/13/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220682042
Principal investigator 1 Boehringer Ingelheim International GmbH $4,326.73 11/13/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220682044
Principal investigator 1 Boehringer Ingelheim International GmbH $850.00 11/13/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220682050
Principal investigator 1 Boehringer Ingelheim International GmbH $4,326.73 11/13/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220682054
Principal investigator 1 Boehringer Ingelheim International GmbH $4,326.73 11/13/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220682060
Principal investigator 1 Boehringer Ingelheim International GmbH $831.00 11/13/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220682062
Principal investigator 1 Boehringer Ingelheim International GmbH $831.00 11/13/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220682068
Principal investigator 1 Boehringer Ingelheim International GmbH $831.00 11/13/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220682070
Principal investigator 1 Boehringer Ingelheim International GmbH $48.48 11/13/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682394
Principal investigator 1 Boehringer Ingelheim International GmbH $90.02 11/13/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682400
Principal investigator 1 Boehringer Ingelheim International GmbH $48.48 11/13/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682408
Principal investigator 1 Boehringer Ingelheim International GmbH $4,293.50 11/12/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682382
Principal investigator 1 Boehringer Ingelheim International GmbH $48.48 11/12/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682390
Principal investigator 1 Boehringer Ingelheim International GmbH $90.02 11/12/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682402
Principal investigator 1 Boehringer Ingelheim International GmbH $4,326.73 11/05/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220682036
Principal investigator 1 Boehringer Ingelheim International GmbH $263.16 11/05/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220682040
Principal investigator 1 Boehringer Ingelheim International GmbH $4,326.73 11/05/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220682048
Principal investigator 1 Boehringer Ingelheim International GmbH $4,326.73 11/05/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220682056
Principal investigator 1 Boehringer Ingelheim International GmbH $4,326.73 11/05/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220682064
Principal investigator 1 Boehringer Ingelheim International GmbH $4,326.73 11/05/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220682066
Principal investigator 1 Boehringer Ingelheim International GmbH $831.00 11/05/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220682078
Principal investigator 1 Boehringer Ingelheim International GmbH $263.16 11/05/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220682080
Principal investigator 1 Boehringer Ingelheim International GmbH $4,326.73 11/05/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220682082
Principal investigator 1 Boehringer Ingelheim International GmbH $4,224.25 11/05/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220682084
Principal investigator 1 Boehringer Ingelheim International GmbH $4,326.73 11/05/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220682086
Principal investigator 1 Boehringer Ingelheim International GmbH $4,224.25 11/05/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220682088
Principal investigator 1 Boehringer Ingelheim International GmbH $138.50 11/05/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682386
Principal investigator 1 Boehringer Ingelheim International GmbH $138.50 11/05/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682388
Principal investigator 1 Boehringer Ingelheim International GmbH $138.50 11/05/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682392
Principal investigator 1 Boehringer Ingelheim International GmbH $138.50 11/05/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682396
Principal investigator 1 Boehringer Ingelheim International GmbH $138.50 11/05/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682404
Principal investigator 1 Boehringer Ingelheim International GmbH $138.50 11/05/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682412
Principal investigator 1 PFIZER INC. $4,745.10 11/04/2025 Non-covered Recipient Entity
FOMAT Medical Research Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 1228729440
Principal investigator 1 Boehringer Ingelheim International GmbH $22,950.00 10/31/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681890
Principal investigator 1 PFIZER INC. $45,108.80 10/31/2025 Non-covered Recipient Entity
FOMAT Medical Research Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 1228741829
Principal investigator 1 Boehringer Ingelheim International GmbH $4,427.86 10/30/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682362
Principal investigator 1 Boehringer Ingelheim International GmbH $831.00 10/29/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681872
Principal investigator 1 Boehringer Ingelheim International GmbH $346.25 10/29/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681876
Principal investigator 1 Boehringer Ingelheim International GmbH $103.88 10/29/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681884
Principal investigator 1 Boehringer Ingelheim International GmbH $159.28 10/29/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681892
Principal investigator 1 Boehringer Ingelheim International GmbH $103.88 10/29/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681896
Principal investigator 1 Boehringer Ingelheim International GmbH $48.48 10/29/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681902
Principal investigator 1 Boehringer Ingelheim International GmbH $831.00 10/29/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681906
Principal investigator 1 Boehringer Ingelheim International GmbH $159.28 10/29/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681910
Principal investigator 1 Boehringer Ingelheim International GmbH $159.28 10/29/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681912
Principal investigator 1 Boehringer Ingelheim International GmbH $831.00 10/29/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681914
Principal investigator 1 Boehringer Ingelheim International GmbH $103.88 10/29/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681918
Principal investigator 1 Boehringer Ingelheim International GmbH $831.00 10/29/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681920
Principal investigator 1 Boehringer Ingelheim International GmbH $159.88 10/29/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681936
Principal investigator 1 Boehringer Ingelheim International GmbH $159.28 10/29/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681942
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 10/29/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681948
Principal investigator 1 Boehringer Ingelheim International GmbH $103.88 10/29/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681958
Principal investigator 1 Boehringer Ingelheim International GmbH $103.88 10/29/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681964
Principal investigator 1 Boehringer Ingelheim International GmbH $103.88 10/29/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681970
Principal investigator 1 Boehringer Ingelheim International GmbH $4,326.73 10/29/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681972
Principal investigator 1 Boehringer Ingelheim International GmbH $11,391.62 10/29/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681974
Principal investigator 1 Boehringer Ingelheim International GmbH $47.88 10/29/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681980
Principal investigator 1 Boehringer Ingelheim International GmbH $4,326.73 10/29/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681984
Principal investigator 1 Boehringer Ingelheim International GmbH $831.00 10/29/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681994
Principal investigator 1 Boehringer Ingelheim International GmbH $484.75 10/29/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220682000
Principal investigator 1 Boehringer Ingelheim International GmbH $159.28 10/29/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220682006
Principal investigator 1 Boehringer Ingelheim International GmbH $4,326.73 10/29/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220682008
Principal investigator 1 Boehringer Ingelheim International GmbH $740.97 10/29/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220682012
Principal investigator 1 Boehringer Ingelheim International GmbH $831.00 10/29/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220682016
Principal investigator 1 Boehringer Ingelheim International GmbH $850.00 10/29/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682346
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 10/29/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682360
Principal investigator 1 Boehringer Ingelheim International GmbH $346.25 10/29/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682364
Principal investigator 1 Boehringer Ingelheim International GmbH $3,764.43 10/27/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681962
Principal investigator 1 Boehringer Ingelheim International GmbH $2,819.86 10/27/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682336
Principal investigator 1 Boehringer Ingelheim International GmbH $677.27 10/27/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682338
Principal investigator 1 Boehringer Ingelheim International GmbH $2,131.52 10/27/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682340
Principal investigator 1 Boehringer Ingelheim International GmbH $2,131.52 10/27/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682342
Principal investigator 1 Boehringer Ingelheim International GmbH $2,819.86 10/27/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682348
Principal investigator 1 Boehringer Ingelheim International GmbH $2,512.39 10/27/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682352
Principal investigator 1 Boehringer Ingelheim International GmbH $2,819.86 10/27/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682354
Principal investigator 1 Boehringer Ingelheim International GmbH $2,512.39 10/27/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682356
Principal investigator 1 Boehringer Ingelheim International GmbH $2,512.39 10/27/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682358
Principal investigator 1 Boehringer Ingelheim International GmbH $16,291.76 10/27/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682366
Principal investigator 1 Boehringer Ingelheim International GmbH $2,512.39 10/27/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682368
Principal investigator 1 Boehringer Ingelheim International GmbH $677.27 10/27/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682370
Principal investigator 1 Boehringer Ingelheim International GmbH $2,131.52 10/27/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682372
Principal investigator 1 Boehringer Ingelheim International GmbH $2,131.52 10/27/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682374
Principal investigator 1 Boehringer Ingelheim International GmbH $2,819.86 10/27/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682376
Principal investigator 1 Boehringer Ingelheim International GmbH $199.80 10/27/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682422
Principal investigator 1 Boehringer Ingelheim International GmbH $7.50 10/24/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220682018
Principal investigator 1 Boehringer Ingelheim International GmbH $7.45 10/24/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220682020
Principal investigator 1 Boehringer Ingelheim International GmbH $80.00 10/24/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220682022
Principal investigator 1 Boehringer Ingelheim International GmbH $325.00 10/24/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220682024
Principal investigator 1 Boehringer Ingelheim International GmbH $52.63 10/23/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681894
Principal investigator 1 Boehringer Ingelheim International GmbH $159.28 10/23/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681926
Principal investigator 1 Boehringer Ingelheim International GmbH $124.65 10/23/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681950
Principal investigator 1 Boehringer Ingelheim International GmbH $69.25 10/23/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681986
Principal investigator 1 Boehringer Ingelheim International GmbH $103.88 10/23/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681998
Principal investigator 1 Boehringer Ingelheim International GmbH $48.48 10/23/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220682002
Principal investigator 1 Boehringer Ingelheim International GmbH $717.43 10/22/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220682026
Principal investigator 1 Boehringer Ingelheim International GmbH $4,326.78 10/17/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681886
Principal investigator 1 Boehringer Ingelheim International GmbH $4,427.88 10/17/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682350
Principal investigator 1 Boehringer Ingelheim International GmbH $303.18 10/16/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682380
Principal investigator 1 Boehringer Ingelheim International GmbH $2,858.63 10/15/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682344
Principal investigator 1 PFIZER INC. $10,642.20 10/15/2025 Non-covered Recipient Entity
FOMAT Medical Research Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 1228741162
Principal investigator 1 Boehringer Ingelheim International GmbH $103.88 10/10/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681922
Principal investigator 1 Boehringer Ingelheim International GmbH $48.48 10/10/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681928
Principal investigator 1 Boehringer Ingelheim International GmbH $159.28 10/10/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681932
Principal investigator 1 Boehringer Ingelheim International GmbH $103.88 10/10/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681934
Principal investigator 1 Boehringer Ingelheim International GmbH $159.28 10/10/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681946
Principal investigator 1 Boehringer Ingelheim International GmbH $48.48 10/10/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681956
Principal investigator 1 Boehringer Ingelheim International GmbH $103.88 10/10/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681960
Principal investigator 1 Boehringer Ingelheim International GmbH $159.28 10/10/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681968
Principal investigator 1 Boehringer Ingelheim International GmbH $103.88 10/10/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681982
Principal investigator 1 Boehringer Ingelheim International GmbH $159.28 10/10/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681996
Principal investigator 1 Boehringer Ingelheim International GmbH $484.75 10/08/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682378
Principal investigator 1 Boehringer Ingelheim International GmbH $103.88 10/03/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681874
Principal investigator 1 Boehringer Ingelheim International GmbH $103.88 10/03/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681878
Principal investigator 1 Boehringer Ingelheim International GmbH $103.88 10/03/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681880
Principal investigator 1 Boehringer Ingelheim International GmbH $103.88 10/03/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681882
Principal investigator 1 Boehringer Ingelheim International GmbH $159.28 10/03/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681888
Principal investigator 1 Boehringer Ingelheim International GmbH $159.28 10/03/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681898
Principal investigator 1 Boehringer Ingelheim International GmbH $159.28 10/03/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681900
Principal investigator 1 Boehringer Ingelheim International GmbH $159.28 10/03/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681904
Principal investigator 1 Boehringer Ingelheim International GmbH $103.88 10/03/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681908
Principal investigator 1 Boehringer Ingelheim International GmbH $103.88 10/03/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681916
Principal investigator 1 Boehringer Ingelheim International GmbH $159.28 10/03/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681924
Principal investigator 1 Boehringer Ingelheim International GmbH $103.88 10/03/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681930
Principal investigator 1 Boehringer Ingelheim International GmbH $103.88 10/03/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681938
Principal investigator 1 Boehringer Ingelheim International GmbH $103.88 10/03/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681940
Principal investigator 1 Boehringer Ingelheim International GmbH $159.28 10/03/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681944
Principal investigator 1 Boehringer Ingelheim International GmbH $159.28 10/03/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681952
Principal investigator 1 Boehringer Ingelheim International GmbH $159.28 10/03/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681954
Principal investigator 1 Boehringer Ingelheim International GmbH $159.28 10/03/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681966
Principal investigator 1 Boehringer Ingelheim International GmbH $103.88 10/03/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681976
Principal investigator 1 Boehringer Ingelheim International GmbH $159.28 10/03/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681978
Principal investigator 1 Boehringer Ingelheim International GmbH $103.88 10/03/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681988
Principal investigator 1 Boehringer Ingelheim International GmbH $103.88 10/03/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681990
Principal investigator 1 Boehringer Ingelheim International GmbH $159.28 10/03/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681992
Principal investigator 1 Boehringer Ingelheim International GmbH $103.88 10/03/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220682004
Principal investigator 1 Boehringer Ingelheim International GmbH $159.28 10/03/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220682010
Principal investigator 1 Boehringer Ingelheim International GmbH $159.28 10/03/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220682014
Principal investigator 1 Boehringer Ingelheim International GmbH $103.88 09/29/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681736
Principal investigator 1 Boehringer Ingelheim International GmbH $103.88 09/29/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681740
Principal investigator 1 Boehringer Ingelheim International GmbH $159.28 09/29/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681742
Principal investigator 1 Boehringer Ingelheim International GmbH $159.28 09/29/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681746
Principal investigator 1 Boehringer Ingelheim International GmbH $103.88 09/29/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681748
Principal investigator 1 Boehringer Ingelheim International GmbH $103.88 09/29/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681754
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 09/29/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681758
Principal investigator 1 Boehringer Ingelheim International GmbH $103.88 09/29/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681768
Principal investigator 1 Boehringer Ingelheim International GmbH $159.28 09/29/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681778
Principal investigator 1 Boehringer Ingelheim International GmbH $159.28 09/29/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681788
Principal investigator 1 Boehringer Ingelheim International GmbH $228.53 09/29/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681792
Principal investigator 1 Boehringer Ingelheim International GmbH $159.28 09/29/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681808
Principal investigator 1 Boehringer Ingelheim International GmbH $103.88 09/29/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681822
Principal investigator 1 Boehringer Ingelheim International GmbH $159.28 09/29/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681826
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 09/29/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681840
Principal investigator 1 Boehringer Ingelheim International GmbH $103.88 09/29/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681842
Principal investigator 1 Boehringer Ingelheim International GmbH $7.50 09/29/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681864
Principal investigator 1 Boehringer Ingelheim International GmbH $7.45 09/29/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681866
Principal investigator 1 Boehringer Ingelheim International GmbH $80.00 09/29/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681868
Principal investigator 1 Boehringer Ingelheim International GmbH $325.00 09/29/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681870
Principal investigator 1 Boehringer Ingelheim International GmbH $677.27 09/29/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682292
Principal investigator 1 Boehringer Ingelheim International GmbH $677.27 09/29/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682300
Principal investigator 1 Boehringer Ingelheim International GmbH $3,404.33 09/29/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682306
Principal investigator 1 Boehringer Ingelheim International GmbH $600.00 09/29/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682312
Principal investigator 1 Boehringer Ingelheim International GmbH $26,326.08 09/29/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682314
Principal investigator 1 Boehringer Ingelheim International GmbH $677.27 09/29/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682316
Principal investigator 1 Boehringer Ingelheim International GmbH $677.27 09/29/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682320
Principal investigator 1 Boehringer Ingelheim International GmbH $17,502.25 09/29/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682330
Principal investigator 1 Boehringer Ingelheim International GmbH $677.27 09/29/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682332
Principal investigator 1 Boehringer Ingelheim International GmbH $256.22 09/26/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681786
Principal investigator 1 Boehringer Ingelheim International GmbH $2,037.34 09/26/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681802
Principal investigator 1 Boehringer Ingelheim International GmbH $519.37 09/26/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682290
Principal investigator 1 Boehringer Ingelheim International GmbH $173.12 09/26/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682294
Principal investigator 1 Boehringer Ingelheim International GmbH $173.12 09/26/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682296
Principal investigator 1 Boehringer Ingelheim International GmbH $484.75 09/26/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682298
Principal investigator 1 Boehringer Ingelheim International GmbH $484.75 09/26/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682302
Principal investigator 1 Boehringer Ingelheim International GmbH $173.12 09/26/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682308
Principal investigator 1 Boehringer Ingelheim International GmbH $484.75 09/26/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682310
Principal investigator 1 Boehringer Ingelheim International GmbH $173.12 09/26/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682322
Principal investigator 1 Boehringer Ingelheim International GmbH $48.47 09/26/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682334
Principal investigator 1 Boehringer Ingelheim International GmbH $259.74 09/24/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681710
Principal investigator 1 Boehringer Ingelheim International GmbH $1,058.50 09/24/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681712
Principal investigator 1 Boehringer Ingelheim International GmbH $6.00 09/24/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681714
Principal investigator 1 Boehringer Ingelheim International GmbH $399.60 09/24/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682286
Principal investigator 1 Boehringer Ingelheim International GmbH $839.50 09/24/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682288
Principal investigator 1 PFIZER INC. $33,258.45 09/24/2025 Non-covered Recipient Entity
FOMAT Medical Research Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 1228748905
Principal investigator 1 Boehringer Ingelheim International GmbH $918.23 09/15/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681716
Principal investigator 1 Boehringer Ingelheim International GmbH $918.23 09/15/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681728
Principal investigator 1 Boehringer Ingelheim International GmbH $966.70 09/15/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681760
Principal investigator 1 Boehringer Ingelheim International GmbH $918.23 09/15/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681782
Principal investigator 1 Boehringer Ingelheim International GmbH $717.41 09/15/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681794
Principal investigator 1 Boehringer Ingelheim International GmbH $717.41 09/15/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681796
Principal investigator 1 Boehringer Ingelheim International GmbH $966.70 09/15/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681806
Principal investigator 1 Boehringer Ingelheim International GmbH $16,150.00 09/15/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681836
Principal investigator 1 Boehringer Ingelheim International GmbH $544.29 09/11/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681718
Principal investigator 1 Boehringer Ingelheim International GmbH $1,804.63 09/11/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681720
Principal investigator 1 Boehringer Ingelheim International GmbH $717.41 09/11/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681722
Principal investigator 1 Boehringer Ingelheim International GmbH $717.41 09/11/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681724
Principal investigator 1 Boehringer Ingelheim International GmbH $138.50 09/11/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681726
Principal investigator 1 Boehringer Ingelheim International GmbH $717.41 09/11/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681738
Principal investigator 1 Boehringer Ingelheim International GmbH $385.02 09/11/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681744
Principal investigator 1 Boehringer Ingelheim International GmbH $1,425.00 09/11/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681750
Principal investigator 1 Boehringer Ingelheim International GmbH $717.41 09/11/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681752
Principal investigator 1 Boehringer Ingelheim International GmbH $400.00 09/11/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681764
Principal investigator 1 Boehringer Ingelheim International GmbH $173.12 09/11/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681770
Principal investigator 1 Boehringer Ingelheim International GmbH $955.62 09/11/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681776
Principal investigator 1 Boehringer Ingelheim International GmbH $90.02 09/11/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681780
Principal investigator 1 Boehringer Ingelheim International GmbH $800.51 09/11/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681784
Principal investigator 1 Boehringer Ingelheim International GmbH $41.55 09/11/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681790
Principal investigator 1 Boehringer Ingelheim International GmbH $415.50 09/11/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681798
Principal investigator 1 Boehringer Ingelheim International GmbH $918.23 09/11/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681800
Principal investigator 1 Boehringer Ingelheim International GmbH $918.23 09/11/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681804
Principal investigator 1 Boehringer Ingelheim International GmbH $34.62 09/11/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681812
Principal investigator 1 Boehringer Ingelheim International GmbH $623.22 09/11/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681814
Principal investigator 1 Boehringer Ingelheim International GmbH $717.41 09/11/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681816
Principal investigator 1 Boehringer Ingelheim International GmbH $717.41 09/11/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681818
Principal investigator 1 Boehringer Ingelheim International GmbH $290.82 09/11/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681820
Principal investigator 1 Boehringer Ingelheim International GmbH $966.70 09/11/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681824
Principal investigator 1 Boehringer Ingelheim International GmbH $1,319.88 09/11/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681828
Principal investigator 1 Boehringer Ingelheim International GmbH $315.78 09/11/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681830
Principal investigator 1 Boehringer Ingelheim International GmbH $1,121.85 09/11/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681832
Principal investigator 1 Boehringer Ingelheim International GmbH $1,402.98 09/11/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681834
Principal investigator 1 Boehringer Ingelheim International GmbH $256.22 09/11/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681838
Principal investigator 1 Boehringer Ingelheim International GmbH $717.41 09/11/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681844
Principal investigator 1 Boehringer Ingelheim International GmbH $973.63 09/11/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681846
Principal investigator 1 Boehringer Ingelheim International GmbH $1,596.88 09/11/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681848
Principal investigator 1 Boehringer Ingelheim International GmbH $717.41 09/11/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681850
Principal investigator 1 Boehringer Ingelheim International GmbH $1,797.70 09/11/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681852
Principal investigator 1 Boehringer Ingelheim International GmbH $717.41 09/11/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681856
Principal investigator 1 Boehringer Ingelheim International GmbH $966.70 09/11/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681860
Principal investigator 1 Boehringer Ingelheim International GmbH $717.41 09/11/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681862
Principal investigator 1 PFIZER INC. $6,588.45 09/09/2025 Non-covered Recipient Entity
FOMAT Medical Research Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 1228770098
Principal investigator 1 Boehringer Ingelheim International GmbH $69.25 09/03/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681730
Principal investigator 1 Boehringer Ingelheim International GmbH $346.25 09/03/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681732
Principal investigator 1 Boehringer Ingelheim International GmbH $277.00 09/03/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681734
Principal investigator 1 Boehringer Ingelheim International GmbH $103.87 09/03/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681756
Principal investigator 1 Boehringer Ingelheim International GmbH $52.63 09/03/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681762
Principal investigator 1 Boehringer Ingelheim International GmbH $173.12 09/03/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681766
Principal investigator 1 Boehringer Ingelheim International GmbH $124.65 09/03/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681772
Principal investigator 1 Boehringer Ingelheim International GmbH $346.25 09/03/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681774
Principal investigator 1 Boehringer Ingelheim International GmbH $346.25 09/03/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681810
Principal investigator 1 Boehringer Ingelheim International GmbH $34.62 09/03/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681854
Principal investigator 1 Boehringer Ingelheim International GmbH $159.27 09/03/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681858
Principal investigator 1 Boehringer Ingelheim International GmbH $34,850.00 09/01/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682304
Principal investigator 1 Boehringer Ingelheim International GmbH $346.25 09/01/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682318
Principal investigator 1 Boehringer Ingelheim International GmbH $3,075.00 09/01/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682324
Principal investigator 1 Boehringer Ingelheim International GmbH $150.00 09/01/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682326
Principal investigator 1 Boehringer Ingelheim International GmbH $1,700.00 09/01/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682328
Principal investigator 1 Boehringer Ingelheim International GmbH $3,404.33 08/28/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682186
Principal investigator 1 Boehringer Ingelheim International GmbH $677.27 08/28/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682196
Principal investigator 1 Boehringer Ingelheim International GmbH $677.27 08/28/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682216
Principal investigator 1 Boehringer Ingelheim International GmbH $174.90 08/26/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682278
Principal investigator 1 Boehringer Ingelheim International GmbH $419.58 08/26/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682280
Principal investigator 1 Boehringer Ingelheim International GmbH $474.50 08/26/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682282
Principal investigator 1 Boehringer Ingelheim International GmbH $5.00 08/26/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682284
Principal investigator 1 Boehringer Ingelheim International GmbH $484.75 08/14/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682254
Principal investigator 1 Boehringer Ingelheim International GmbH $554.00 08/14/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682264
Principal investigator 1 Boehringer Ingelheim International GmbH $346.25 08/13/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681696
Principal investigator 1 Boehringer Ingelheim International GmbH $450.13 08/13/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681698
Principal investigator 1 Boehringer Ingelheim International GmbH $5,540.00 08/13/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681700
Principal investigator 1 Boehringer Ingelheim International GmbH $124.65 08/13/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682174
Principal investigator 1 Boehringer Ingelheim International GmbH $173.13 08/13/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682180
Principal investigator 1 Boehringer Ingelheim International GmbH $159.28 08/13/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682190
Principal investigator 1 Boehringer Ingelheim International GmbH $7,650.00 08/13/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682194
Principal investigator 1 Boehringer Ingelheim International GmbH $124.65 08/13/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682198
Principal investigator 1 Boehringer Ingelheim International GmbH $124.65 08/13/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682202
Principal investigator 1 Boehringer Ingelheim International GmbH $124.65 08/13/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682208
Principal investigator 1 Boehringer Ingelheim International GmbH $159.28 08/13/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682210
Principal investigator 1 Boehringer Ingelheim International GmbH $173.13 08/13/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682214
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 08/13/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682218
Principal investigator 1 Boehringer Ingelheim International GmbH $173.13 08/13/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682224
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 08/13/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682228
Principal investigator 1 Boehringer Ingelheim International GmbH $124.65 08/13/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682230
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 08/13/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682232
Principal investigator 1 Boehringer Ingelheim International GmbH $124.65 08/13/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682236
Principal investigator 1 Boehringer Ingelheim International GmbH $96.96 08/13/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682238
Principal investigator 1 Boehringer Ingelheim International GmbH $400.00 08/13/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682244
Principal investigator 1 Boehringer Ingelheim International GmbH $159.28 08/13/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682250
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 08/13/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682258
Principal investigator 1 Boehringer Ingelheim International GmbH $124.65 08/13/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682260
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 08/13/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682262
Principal investigator 1 ModernaTX, Inc. $1,400.00 08/08/2025 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252967839
Principal investigator 1 PFIZER INC. $700.00 08/05/2025 Non-covered Recipient Entity
FOMAT Medical Research Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 1228761612
Principal investigator 1 Boehringer Ingelheim International GmbH $138.50 08/04/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682176
Principal investigator 1 Boehringer Ingelheim International GmbH $207.75 08/04/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682178
Principal investigator 1 Boehringer Ingelheim International GmbH $48.48 08/04/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682182
Principal investigator 1 Boehringer Ingelheim International GmbH $675.00 08/04/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682184
Principal investigator 1 Boehringer Ingelheim International GmbH $138.50 08/04/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682188
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 08/04/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682192
Principal investigator 1 Boehringer Ingelheim International GmbH $110.80 08/04/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682200
Principal investigator 1 Boehringer Ingelheim International GmbH $124.65 08/04/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682204
Principal investigator 1 Boehringer Ingelheim International GmbH $90.03 08/04/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682206
Principal investigator 1 Boehringer Ingelheim International GmbH $2,400.00 08/04/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682212
Principal investigator 1 Boehringer Ingelheim International GmbH $138.50 08/04/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682220
Principal investigator 1 Boehringer Ingelheim International GmbH $138.50 08/04/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682222
Principal investigator 1 Boehringer Ingelheim International GmbH $110.80 08/04/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682226
Principal investigator 1 Boehringer Ingelheim International GmbH $90.03 08/04/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682234
Principal investigator 1 Boehringer Ingelheim International GmbH $138.50 08/04/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682240
Principal investigator 1 Boehringer Ingelheim International GmbH $90.03 08/04/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682242
Principal investigator 1 Boehringer Ingelheim International GmbH $4,293.50 08/04/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682246
Principal investigator 1 Boehringer Ingelheim International GmbH $48.48 08/04/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682248
Principal investigator 1 Boehringer Ingelheim International GmbH $138.50 08/04/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682252
Principal investigator 1 Boehringer Ingelheim International GmbH $138.50 08/04/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682256
Principal investigator 1 Boehringer Ingelheim International GmbH $4,293.50 08/04/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682266
Principal investigator 1 Boehringer Ingelheim International GmbH $138.50 07/31/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681602
Principal investigator 1 Boehringer Ingelheim International GmbH $138.50 07/31/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681628
Principal investigator 1 Boehringer Ingelheim International GmbH $138.50 07/31/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681630
Principal investigator 1 Boehringer Ingelheim International GmbH $138.50 07/31/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681632
Principal investigator 1 Boehringer Ingelheim International GmbH $277.00 07/31/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681636
Principal investigator 1 Boehringer Ingelheim International GmbH $138.50 07/31/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681638
Principal investigator 1 Boehringer Ingelheim International GmbH $138.50 07/31/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681640
Principal investigator 1 Boehringer Ingelheim International GmbH $138.50 07/31/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681642
Principal investigator 1 Boehringer Ingelheim International GmbH $5,950.00 07/30/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681596
Principal investigator 1 Boehringer Ingelheim International GmbH $400.00 07/30/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681598
Principal investigator 1 Boehringer Ingelheim International GmbH $2,037.34 07/30/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681606
Principal investigator 1 Boehringer Ingelheim International GmbH $2,325.00 07/30/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681620
Principal investigator 1 Boehringer Ingelheim International GmbH $2,400.00 07/30/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681622
Principal investigator 1 Boehringer Ingelheim International GmbH $484.75 07/30/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681634
Principal investigator 1 Boehringer Ingelheim International GmbH $138.50 07/30/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681658
Principal investigator 1 Boehringer Ingelheim International GmbH $5,258.88 07/30/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682140
Principal investigator 1 Boehringer Ingelheim International GmbH $26,154.34 07/30/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682142
Principal investigator 1 Boehringer Ingelheim International GmbH $16,347.16 07/30/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682144
Principal investigator 1 Boehringer Ingelheim International GmbH $677.27 07/30/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682146
Principal investigator 1 Boehringer Ingelheim International GmbH $26,154.34 07/30/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682150
Principal investigator 1 Boehringer Ingelheim International GmbH $4,427.88 07/30/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682152
Principal investigator 1 Boehringer Ingelheim International GmbH $17,502.25 07/30/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682156
Principal investigator 1 Boehringer Ingelheim International GmbH $110.80 07/30/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682158
Principal investigator 1 Boehringer Ingelheim International GmbH $90.03 07/30/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682160
Principal investigator 1 Boehringer Ingelheim International GmbH $26,154.34 07/30/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682162
Principal investigator 1 Boehringer Ingelheim International GmbH $16,347.16 07/30/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682164
Principal investigator 1 Boehringer Ingelheim International GmbH $677.27 07/30/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682166
Principal investigator 1 Boehringer Ingelheim International GmbH $110.80 07/30/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682168
Principal investigator 1 Boehringer Ingelheim International GmbH $484.75 07/30/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682170
Principal investigator 1 Boehringer Ingelheim International GmbH $90.03 07/30/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682172
Principal investigator 1 Boehringer Ingelheim International GmbH $599.40 07/28/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681702
Principal investigator 1 Boehringer Ingelheim International GmbH $1,350.50 07/28/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681704
Principal investigator 1 Boehringer Ingelheim International GmbH $126.10 07/28/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681706
Principal investigator 1 Boehringer Ingelheim International GmbH $12.00 07/28/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681708
Principal investigator 1 Boehringer Ingelheim International GmbH $104.94 07/28/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682268
Principal investigator 1 Boehringer Ingelheim International GmbH $19.98 07/28/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682270
Principal investigator 1 Boehringer Ingelheim International GmbH $109.50 07/28/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682272
Principal investigator 1 Boehringer Ingelheim International GmbH $126.10 07/28/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682274
Principal investigator 1 Boehringer Ingelheim International GmbH $3.00 07/28/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682276
Principal investigator 1 Boehringer Ingelheim International GmbH $850.00 07/24/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681580
Principal investigator 1 Boehringer Ingelheim International GmbH $850.00 07/24/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681584
Principal investigator 1 Boehringer Ingelheim International GmbH $850.00 07/24/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681586
Principal investigator 1 Boehringer Ingelheim International GmbH $850.00 07/24/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681588
Principal investigator 1 Boehringer Ingelheim International GmbH $850.00 07/24/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681592
Principal investigator 1 Boehringer Ingelheim International GmbH $850.00 07/24/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681594
Principal investigator 1 Boehringer Ingelheim International GmbH $850.00 07/24/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681604
Principal investigator 1 Boehringer Ingelheim International GmbH $850.00 07/24/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681608
Principal investigator 1 Boehringer Ingelheim International GmbH $850.00 07/24/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681626
Principal investigator 1 Boehringer Ingelheim International GmbH $850.00 07/24/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681644
Principal investigator 1 Boehringer Ingelheim International GmbH $850.00 07/24/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681646
Principal investigator 1 Boehringer Ingelheim International GmbH $850.00 07/24/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681650
Principal investigator 1 Boehringer Ingelheim International GmbH $850.00 07/24/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681654
Principal investigator 1 Boehringer Ingelheim International GmbH $850.00 07/24/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681660
Principal investigator 1 Boehringer Ingelheim International GmbH $850.00 07/24/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681662
Principal investigator 1 Boehringer Ingelheim International GmbH $850.00 07/24/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681664
Principal investigator 1 Boehringer Ingelheim International GmbH $850.00 07/24/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681666
Principal investigator 1 Boehringer Ingelheim International GmbH $850.00 07/24/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681670
Principal investigator 1 Boehringer Ingelheim International GmbH $850.00 07/24/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681672
Principal investigator 1 Boehringer Ingelheim International GmbH $850.00 07/24/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681674
Principal investigator 1 Boehringer Ingelheim International GmbH $484.75 07/23/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681600
Principal investigator 1 Boehringer Ingelheim International GmbH $484.75 07/23/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681610
Principal investigator 1 Boehringer Ingelheim International GmbH $311.07 07/17/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681686
Principal investigator 1 Boehringer Ingelheim International GmbH $90.00 07/17/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681688
Principal investigator 1 Boehringer Ingelheim International GmbH $124.00 07/17/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681690
Principal investigator 1 Boehringer Ingelheim International GmbH $108.00 07/17/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681692
Principal investigator 1 Boehringer Ingelheim International GmbH $484.75 07/16/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681582
Principal investigator 1 Boehringer Ingelheim International GmbH $484.75 07/16/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681590
Principal investigator 1 Boehringer Ingelheim International GmbH $4,326.78 07/16/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681612
Principal investigator 1 Boehringer Ingelheim International GmbH $4,326.78 07/16/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681614
Principal investigator 1 Boehringer Ingelheim International GmbH $4,326.78 07/16/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681616
Principal investigator 1 Boehringer Ingelheim International GmbH $4,326.78 07/16/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681618
Principal investigator 1 Boehringer Ingelheim International GmbH $3,400.00 07/16/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681624
Principal investigator 1 Boehringer Ingelheim International GmbH $4,326.78 07/16/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681648
Principal investigator 1 Boehringer Ingelheim International GmbH $4,326.78 07/16/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681652
Principal investigator 1 Boehringer Ingelheim International GmbH $4,326.78 07/16/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681656
Principal investigator 1 Boehringer Ingelheim International GmbH $4,326.78 07/16/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681668
Principal investigator 1 Boehringer Ingelheim International GmbH $484.75 07/16/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682148
Principal investigator 1 Boehringer Ingelheim International GmbH $484.75 07/16/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682154
Principal investigator 1 PFIZER INC. $2,050.00 07/16/2025 Non-covered Recipient Entity
FOMAT Medical Research Inc
AN INTERVENTIONAL PHASE 23 ADAPTIVE MULTICENTER RANDOMIZED DOUBLEBLIND STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ORAL SISUNATOVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULTS WITH RESPIRATORY SYNCYTIAL VIRUS INFECTION WHO ARE AT RISK OF PROGRESSION TO SEVERE ILLNESS No dispute reported 06/30/2026 1228782723
Principal investigator 1 Boehringer Ingelheim International GmbH $80.00 07/15/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681684
Principal investigator 1 Boehringer Ingelheim International GmbH $4.50 07/09/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681676
Principal investigator 1 Boehringer Ingelheim International GmbH $4.50 07/09/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681678
Principal investigator 1 Boehringer Ingelheim International GmbH $4.50 07/09/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681680
Principal investigator 1 Boehringer Ingelheim International GmbH $4.50 07/09/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681682
Principal investigator 1 Boehringer Ingelheim International GmbH $190.50 07/09/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681694
Principal investigator 1 ModernaTX, Inc. $140.00 07/09/2025 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252967845
Principal investigator 1 ModernaTX, Inc. $1,000.00 07/09/2025 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252967877
Principal investigator 1 Boehringer Ingelheim International GmbH $4,672.99 06/30/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681472
Principal investigator 1 Boehringer Ingelheim International GmbH $4,672.99 06/30/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681482
Principal investigator 1 Boehringer Ingelheim International GmbH $350.00 06/30/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681488
Principal investigator 1 Boehringer Ingelheim International GmbH $350.00 06/30/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681492
Principal investigator 1 Boehringer Ingelheim International GmbH $4,672.99 06/30/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681498
Principal investigator 1 Boehringer Ingelheim International GmbH $4,672.99 06/30/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681504
Principal investigator 1 Boehringer Ingelheim International GmbH $4,672.99 06/30/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681512
Principal investigator 1 Boehringer Ingelheim International GmbH $4,672.99 06/30/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681516
Principal investigator 1 Boehringer Ingelheim International GmbH $4,672.99 06/30/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681524
Principal investigator 1 Boehringer Ingelheim International GmbH $4,672.99 06/30/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681530
Principal investigator 1 Boehringer Ingelheim International GmbH $4,672.99 06/30/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681536
Principal investigator 1 Boehringer Ingelheim International GmbH $4,672.99 06/30/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681554
Principal investigator 1 Boehringer Ingelheim International GmbH $2,037.34 06/27/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681474
Principal investigator 1 Boehringer Ingelheim International GmbH $850.00 06/27/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681506
Principal investigator 1 Boehringer Ingelheim International GmbH $850.00 06/27/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681518
Principal investigator 1 Boehringer Ingelheim International GmbH $2,808.78 06/27/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681538
Principal investigator 1 Boehringer Ingelheim International GmbH $850.00 06/27/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681540
Principal investigator 1 Boehringer Ingelheim International GmbH $850.00 06/27/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681550
Principal investigator 1 ModernaTX, Inc. $3,588.00 06/25/2025 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252967849
Principal investigator 1 ModernaTX, Inc. $9,324.50 06/25/2025 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252967859
Principal investigator 1 ModernaTX, Inc. $488.18 06/25/2025 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252967865
Principal investigator 1 ModernaTX, Inc. $6,112.50 06/25/2025 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252967871
Principal investigator 1 ModernaTX, Inc. $22,277.97 06/25/2025 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252967885
Principal investigator 1 ModernaTX, Inc. $81,708.72 06/25/2025 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252967889
Principal investigator 1 Boehringer Ingelheim International GmbH $59.94 06/24/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681574
Principal investigator 1 Boehringer Ingelheim International GmbH $182.50 06/24/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681576
Principal investigator 1 Boehringer Ingelheim International GmbH $2.00 06/24/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681578
Principal investigator 1 Boehringer Ingelheim International GmbH $19.98 06/24/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682136
Principal investigator 1 Boehringer Ingelheim International GmbH $620.50 06/24/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682138
Principal investigator 1 Boehringer Ingelheim International GmbH $138.50 06/23/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681468
Principal investigator 1 Boehringer Ingelheim International GmbH $138.50 06/23/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681470
Principal investigator 1 Boehringer Ingelheim International GmbH $138.50 06/23/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681476
Principal investigator 1 Boehringer Ingelheim International GmbH $138.50 06/23/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681480
Principal investigator 1 Boehringer Ingelheim International GmbH $138.50 06/23/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681484
Principal investigator 1 Boehringer Ingelheim International GmbH $138.50 06/23/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681486
Principal investigator 1 Boehringer Ingelheim International GmbH $138.50 06/23/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681490
Principal investigator 1 Boehringer Ingelheim International GmbH $138.50 06/23/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681494
Principal investigator 1 Boehringer Ingelheim International GmbH $138.50 06/23/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681496
Principal investigator 1 Boehringer Ingelheim International GmbH $138.50 06/23/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681500
Principal investigator 1 Boehringer Ingelheim International GmbH $138.50 06/23/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681502
Principal investigator 1 Boehringer Ingelheim International GmbH $138.50 06/23/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681508
Principal investigator 1 Boehringer Ingelheim International GmbH $138.50 06/23/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681510
Principal investigator 1 Boehringer Ingelheim International GmbH $138.50 06/23/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681514
Principal investigator 1 Boehringer Ingelheim International GmbH $138.50 06/23/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681520
Principal investigator 1 Boehringer Ingelheim International GmbH $138.50 06/23/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681522
Principal investigator 1 Boehringer Ingelheim International GmbH $138.50 06/23/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681526
Principal investigator 1 Boehringer Ingelheim International GmbH $138.50 06/23/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681528
Principal investigator 1 Boehringer Ingelheim International GmbH $138.50 06/23/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681532
Principal investigator 1 Boehringer Ingelheim International GmbH $138.50 06/23/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681534
Principal investigator 1 Boehringer Ingelheim International GmbH $138.50 06/23/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681542
Principal investigator 1 Boehringer Ingelheim International GmbH $138.50 06/23/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681544
Principal investigator 1 Boehringer Ingelheim International GmbH $138.50 06/23/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681546
Principal investigator 1 Boehringer Ingelheim International GmbH $138.50 06/23/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681548
Principal investigator 1 Boehringer Ingelheim International GmbH $138.50 06/23/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681552
Principal investigator 1 Boehringer Ingelheim International GmbH $5,950.00 06/16/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681478
Principal investigator 1 ModernaTX, Inc. $1,141.95 06/02/2025 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252967875
Principal investigator 1 Boehringer Ingelheim International GmbH $2,418.21 05/28/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681558
Principal investigator 1 Boehringer Ingelheim International GmbH $677.27 05/28/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681560
Principal investigator 1 Boehringer Ingelheim International GmbH $677.27 05/28/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681562
Principal investigator 1 ModernaTX, Inc. $4,305.28 05/28/2025 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252967847
Principal investigator 1 ModernaTX, Inc. $1,050.00 05/28/2025 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252967855
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 05/27/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681572
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 05/27/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682132
Principal investigator 1 Boehringer Ingelheim International GmbH $219.00 05/27/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682134
Principal investigator 1 PFIZER INC. $1,050.00 05/23/2025 Non-covered Recipient Entity
FOMAT Medical Research Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 1228784207
Principal investigator 1 Boehringer Ingelheim International GmbH $213.29 05/22/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681556
Principal investigator 1 Boehringer Ingelheim International GmbH $400.00 04/30/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681460
Principal investigator 1 Boehringer Ingelheim International GmbH $15,718.37 04/28/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681462
Principal investigator 1 Boehringer Ingelheim International GmbH $3,407.10 04/28/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681464
Principal investigator 1 Boehringer Ingelheim International GmbH $104.94 04/23/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681564
Principal investigator 1 Boehringer Ingelheim International GmbH $199.80 04/23/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681566
Principal investigator 1 Boehringer Ingelheim International GmbH $985.50 04/23/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681568
Principal investigator 1 Boehringer Ingelheim International GmbH $5.00 04/23/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681570
Principal investigator 1 PFIZER INC. $19,500.00 04/08/2025 Non-covered Recipient Entity
FOMAT Medical Research Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 1228779684
Principal investigator 1 Boehringer Ingelheim International GmbH $42.86 04/04/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681466
Principal investigator 1 ModernaTX, Inc. $1,000.00 04/01/2025 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252967841
Principal investigator 1 ModernaTX, Inc. $2,000.00 04/01/2025 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252967873
Principal investigator 1 ModernaTX, Inc. $1,092.78 03/26/2025 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252967853
Principal investigator 1 Boehringer Ingelheim International GmbH $99.90 03/25/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681456
Principal investigator 1 Boehringer Ingelheim International GmbH $1,058.50 03/25/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681458
Principal investigator 1 PFIZER INC. $2,875.50 03/14/2025 Non-covered Recipient Entity
FOMAT Medical Research Inc
AN INTERVENTIONAL PHASE 23 ADAPTIVE MULTICENTER RANDOMIZED DOUBLEBLIND STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ORAL SISUNATOVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULTS WITH RESPIRATORY SYNCYTIAL VIRUS INFECTION WHO ARE AT RISK OF PROGRESSION TO SEVERE ILLNESS No dispute reported 06/30/2026 1228788987
Principal investigator 1 ModernaTX, Inc. $252.46 02/26/2025 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252967881
Principal investigator 1 Boehringer Ingelheim International GmbH $116.60 02/25/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681448
Principal investigator 1 Boehringer Ingelheim International GmbH $474.50 02/25/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681450
Principal investigator 1 Boehringer Ingelheim International GmbH $97.70 02/25/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681452
Principal investigator 1 Boehringer Ingelheim International GmbH $12.60 02/25/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681454
Principal investigator 1 Boehringer Ingelheim International GmbH $209.88 02/25/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682122
Principal investigator 1 Boehringer Ingelheim International GmbH $139.86 02/25/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682124
Principal investigator 1 Boehringer Ingelheim International GmbH $730.00 02/25/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682126
Principal investigator 1 Boehringer Ingelheim International GmbH $58.62 02/25/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682128
Principal investigator 1 Boehringer Ingelheim International GmbH $6.00 02/25/2025 Non-covered Recipient Entity
Fomat Medical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220682130
Principal investigator 1 ModernaTX, Inc. $757.38 02/21/2025 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252967883
Principal investigator 1 ModernaTX, Inc. $4,200.00 02/03/2025 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252967857
Principal investigator 1 ModernaTX, Inc. $406.28 01/29/2025 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252967861
Principal investigator 1 ModernaTX, Inc. $110.05 01/29/2025 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252967867
Principal investigator 1 ModernaTX, Inc. $1,000.00 01/29/2025 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252967879
Principal investigator 1 ModernaTX, Inc. $1,900.00 01/29/2025 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252967887
Principal investigator 1 Boehringer Ingelheim International GmbH $151.58 01/27/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681438
Principal investigator 1 Boehringer Ingelheim International GmbH $139.86 01/27/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681440
Principal investigator 1 Boehringer Ingelheim International GmbH $620.50 01/27/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681442
Principal investigator 1 Boehringer Ingelheim International GmbH $39.08 01/27/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681444
Principal investigator 1 Boehringer Ingelheim International GmbH $5.00 01/27/2025 Non-covered Recipient Entity
Fomat Medical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220681446
Principal investigator 1 Eli Lilly and Company $82,590.00 01/21/2025 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1187881750
Principal investigator 1 Eli Lilly and Company $1,913.02 01/21/2025 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1187883714
Principal investigator 1 ModernaTX, Inc. $2,650.83 01/17/2025 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252967851
Principal investigator 1 PFIZER INC. $374.00 01/14/2025 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 1228736151
Principal investigator 1 Amgen Inc. $372,273.93 01/07/2025 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 513 in Participants With Obesity No dispute reported 06/30/2026 1246641445
Principal investigator 1 Alnylam Pharmaceuticals Inc. $914.00 01/06/2025 Non-covered Recipient Entity
Fomat Medical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215513671